Robeco Institutional Asset Management B.V. Boosts Stock Position in Humana Inc. (NYSE:HUM)

Robeco Institutional Asset Management B.V. raised its position in shares of Humana Inc. (NYSE:HUM - Free Report) by 502.0% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 48,541 shares of the insurance provider's stock after buying an additional 40,478 shares during the period. Robeco Institutional Asset Management B.V.'s holdings in Humana were worth $12,844,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently bought and sold shares of the business. Revolve Wealth Partners LLC acquired a new stake in shares of Humana in the fourth quarter valued at approximately $202,000. New York Life Investment Management LLC grew its position in shares of Humana by 1.1% during the 4th quarter. New York Life Investment Management LLC now owns 18,049 shares of the insurance provider's stock worth $4,579,000 after buying an additional 205 shares during the period. Mn Services Vermogensbeheer B.V. raised its stake in shares of Humana by 1.7% during the fourth quarter. Mn Services Vermogensbeheer B.V. now owns 48,012 shares of the insurance provider's stock worth $12,181,000 after buying an additional 800 shares during the last quarter. Oppenheimer & Co. Inc. lifted its holdings in Humana by 17.2% in the fourth quarter. Oppenheimer & Co. Inc. now owns 3,313 shares of the insurance provider's stock valued at $841,000 after buying an additional 486 shares during the period. Finally, Proficio Capital Partners LLC bought a new position in Humana in the fourth quarter valued at approximately $14,097,000. Institutional investors own 92.38% of the company's stock.

Humana Stock Performance

Shares of NYSE:HUM traded up $0.13 during trading on Monday, hitting $242.01. The stock had a trading volume of 127,234 shares, compared to its average volume of 1,800,733. Humana Inc. has a 12-month low of $212.45 and a 12-month high of $406.46. The stock has a 50-day simple moving average of $241.94 and a two-hundred day simple moving average of $259.20. The company has a quick ratio of 1.91, a current ratio of 1.91 and a debt-to-equity ratio of 0.71. The stock has a market capitalization of $29.21 billion, a price-to-earnings ratio of 17.16, a price-to-earnings-growth ratio of 1.82 and a beta of 0.43.

Humana (NYSE:HUM - Get Free Report) last issued its quarterly earnings results on Wednesday, April 30th. The insurance provider reported $11.58 EPS for the quarter, topping the consensus estimate of $10.07 by $1.51. Humana had a net margin of 1.42% and a return on equity of 14.47%. The company had revenue of $32.11 billion during the quarter, compared to analyst estimates of $32 billion. During the same quarter in the previous year, the firm earned $7.23 EPS. The firm's revenue was up 8.4% compared to the same quarter last year. On average, equities research analysts expect that Humana Inc. will post 16.47 earnings per share for the current fiscal year.

Humana Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, July 25th. Investors of record on Friday, June 27th will be paid a dividend of $0.885 per share. The ex-dividend date of this dividend is Friday, June 27th. This represents a $3.54 annualized dividend and a yield of 1.46%. Humana's payout ratio is 25.04%.

Analyst Upgrades and Downgrades

HUM has been the topic of a number of analyst reports. Guggenheim began coverage on Humana in a research note on Wednesday, April 9th. They issued a "buy" rating and a $326.00 price target on the stock. Cantor Fitzgerald reiterated a "neutral" rating and issued a $290.00 target price on shares of Humana in a research note on Thursday, May 1st. Raymond James Financial raised Humana from a "market perform" rating to an "outperform" rating and set a $315.00 price target for the company in a report on Thursday, May 1st. Oppenheimer increased their target price on Humana from $300.00 to $310.00 and gave the stock an "outperform" rating in a research note on Thursday, May 1st. Finally, Wall Street Zen raised shares of Humana from a "hold" rating to a "buy" rating in a report on Friday. Sixteen investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Hold" and a consensus target price of $280.76.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.